Appendix
Clinical Trials
INTERVENTIONAL NEURORADIOLOGY HUMANITARIAN USE DEVICES (HUDS)
Dr. Michael Brant-Zawadzki, Principal Investigator: Boston Scientific Target
Neuroform™ Microdelivery Stent System and Neuroform EZ Stent System
for Cerebral Aneurysm (H020002).
Dr. Wallace Peck, Principal Investigator: Stryker Corporation Wingspan™
Stent System with Gateway™ PTA Balloon Catheter for Cerebral Aneurysm
(H050001).
Dr. Wallace Peck, Principal Investigator: MicroVention Lowprofile Visualized
Intraluminal Support (LVIS®) or LVIS Jr. Humanitarian Use Device (“LVIS
HUD”) for Cerebral Aneurysm.
STROKE CLINICAL RESEARCH
Dr. David Brown, Principal Investigator: Sleep SMART “Sleep for Stroke
Management And Recovery Trial: Phase 3 Multicenter, Prospective Randomized
Open-, Blinded-Endpoint (PROBE) Controlled Trial To Test Whether Treatment
Of Obstructive Sleep Apnea (OSA) With Continuous Positive Airway Pressure
Is Effective For Secondary Prevention And Recovery After Stroke.”
Funded By NINDS.
ALZHEIMER’S DISEASE CLINICAL RESEARCH
Dr. William Shankle, Principal Investigator: F. Hoffman-La Roche Protocol
BN29552 “CREAD”: A Phase III, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab
in Patients with Prodromal to Mild Alzheimer’s Disease.
Dr. William Shankle, Principal Investigator: F. Hoffman-La Roche Protocol
BN40031: A Multicenter, Open-Label, Long- Term Extension Of Phase III
Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer’s Disease.
Dr. William Shankle, Principal Investigator: Biogen 221AD302 “EMERGE”:
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects
with Early Alzheimer’s Disease.
Dr. William Shankle, Principal Investigator: Eli Lilly Protocol I5T-MC-AACG
“TRAILBLAZER-ALZ”Assessment of Safety, Tolerability and Efficacy
of LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic
Alzheimer’s Disease.
Dr. William Shankle, Principal Investigator: Biogen 251AD201 “TANGO”
- “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects
with Mild Cognitive Impairment due to Alzheimer’s Disease or with
Mild Alzheimer’s Disease”.
Dr. William Shankle, Principal Investigator: COCOA: Coaching for Cognition
in Alzheimer’s Disease.
